Peroxisome proliferator-activated receptor α (PPARα) and atherosclerosis

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 5, Issue 6, 2005, Pages 513-525

  Gouni Berthold, Ioanna ^a   Krone, W ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Atherosclerosis; Cholesterol; Endothelial cell; Fibrates; Macrophage; Monocyte; Peroxisome proliferator activated receptor ; T lymphocyte; Triglyceride; Vascular smooth muscle cell

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BEZAFIBRATE; CIPROFIBRATE; FENOFIBRATE; GEMFIBROZIL; LIGAND; LIPID; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; RAGAGLITAZAR; ROSIGLITAZONE; TESAGLITAZAR;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; BODY WEIGHT DISORDER; CELL ADHESION; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; ENDOTHELIUM CELL; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; INFLAMMATION; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LYMPHOCYTE ACTIVATION; MACROPHAGE; MONOCYTE; NONHUMAN; PRIMARY PREVENTION; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; VASCULAR SMOOTH MUSCLE; WEIGHT GAIN;

ANIMALS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; LIPID METABOLISM; MODELS, BIOLOGICAL; PPAR ALPHA;

EID: 29444451708     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800605774962022     Document Type: Review

References (170)

1. Desvergne, B., Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20, 649-688.
2. Ferre, P. The biology of peroxisome proliferator-activated receptors. Diabetes, 2004, 53, S43-S50.
3. Neve, B., Fruchart, J., Staels, B. Role of peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharmacol., 2000, 60, 1245-1250.
4. Bishop-Bailey, D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol., 2000, 129, 823-834.
5. Ziouzenkova, O., Perrey, S., Asatryan, L., Hwang, J., MacNaul, K.L., Moller, D.E., Rader, D.J., Sevanian, A., Zechner, R., Hoefler, G., Plutzky, J. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role of lipoprotein lipase. Proc. Natl. Acad. Sci. USA, 1997, 94, 4312-4317.
6. Fruchart, J.C., Duriez, P., Staels, B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing liporotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol., 1999, 10, 245-257.
7. Frohnert, B.I., Hui, T.Y., Bernlohr, D.A. Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J. Biol. Chem., 1999, 274, 3970-3977.
8. Motojima, K. Differential effects of PPARalpha activators on induction of ectopic expression of tissue-specific fatty acid binding protein genes in the mouse liver. Int. J. Biochem. Cell. Biol., 2000, 32, 1085-1092.
9. Mascaro, C., Acosta, E., Ortiz, J.A., Marrero, P.F., Hegardt, F.G., Haro, D. Control of human muscle-type carnitine palmitoyl-transferase I gene transcription by peroxisome proliferator-activated receptor. J. Biol. Chem., 1998, 273, 8560-8563.
10. Osumi, T., Wen, J.K., Hashimoto, T. Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene. Biochem. Biophys. Res. Commun., 1991, 175, 866-871.
11. van Raalte, D.H., Li, M., Pritchard, P.H., Wasan, K.M. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharmaceut. Res., 2004, 21, 1531-1538.
12. Knight, B.L., Patel, D.D., Humphreys, S.M., Wiggins, D., Gibbons, G.F. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. J. Lipid Res., 2003, 44, 2049-2058.
13. Schoonjans, K., Staels, B., Auwerx, J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res., 1996, 37, 907-925.
14. Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L., Fernandez-Salguero, P.M., Westphal, H., Gonzales, F.J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferation. Mol. Cell. Biol., 1995, 15, 3012-3022.
15. Delerive, P., Fruchart, J.C., Staels, B. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol., 2001, 169, 453-459.
16. Devchand, P.R., Keller, H., Peters, J.M., Vazquez, M., Gonzales, F.J., Wahli, W. The PPARalpha-leukotriene B4 pathway to inflammatory control. Nature, 1996, 384, 39-43.
17. Chinetti, G., Griglio, S., Antonucci, M., Torra, I.P., Delerive, P., Majd, Z., Fruchart, J.C., Chapman, J., Najib, J., Staels, B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem., 1998, 273, 25573-25580.
18. Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J.M., Gonzalez, F.J., Fruchart, J.C., Tedgui, A., Haegeman, G., Staels,B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NFkB and AP-1. J. Biol. Chem., 1999, 274, 32048-32054.
19. Poynter, M.E., Daynes, R.A. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem., 1998, 273, 32833-32841.
20. Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I.P., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J.C., Najib, J., Maclouf, J., Tedgui, A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature, 1998, 393, 790-793.
21. Kleeman, R., Gervois, P.P., Verschuren, L., Staels, B., Princen, H.M., Kooistra, T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkB-C/EBP-beta complex formation. Blood, 2003, 101, 545-551.
22. Gervois, P., Vu-Dac, N., Kleemann, R., Kockx, M., Dubois, G., Laine, B., Kosykh, V., Fruchart, J.C., Kooistra, T., Staels,B. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonist via inhibition of CCAAT box/enhancer-binding protein beta. J. Biol. Chem., 2001, 276, 33471-33477.
23. Evans, R.M., Barish, G.D., Wang, Y.-X. PPARs and the complex journey to obesity. Nat. Med., 2004, 10, 1-7.
24. Gilde, A.J., van der Lee, K.A., Willemsen, P.H., Chinetti, G., van der Leij, F.R., van der Vusse, G.J., Staels, B., van Bilsen, M. Peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta/delta, but not PPARgamma modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res., 2003, 92, 518-524.
25. Barak, Y., Liao, D., He, W., Ong, E.s., Nelson, M.C., Olefsky, J.M., Boland, R., Evans, R.M. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. USA, 2002, 99, 303-308.
26. Peters, J.M., Lee, S.S., Ii, W., Ward, J.M., Gavrilova, O., Everett, C., Reitman, M.L., Hudson, L.D., Gonsalez, F.J. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta/delta. Mol. Cell. Biol., 2000, 20, 5119-5128.
27. Leibowitz, M.D., Fievet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Bergera, J., Cullinan, C.A., Sparrow, C.P., Baffic, J., Berger, G.D., Santini, C., Maequis, R.W., Tolamn, R.L., Smith, R.G., Moller, D.E., Auwerx, J. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett., 2000, 473, 333-336.
28. Oliver, W.R., Shenk, J.L., Snaith, M.R., Russeell, C.S., Plunket, K.D., Bodkin, N.L., Lewis, M.C., Winegar, D.A., Sznaidman, M.L., Lambert, M.H., Xu, H.E., Sternbach, D.D., Kliewer, S.A., Hansen, B.C., Wilson, T.M. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA, 2001, 98, 5306-5311.
29. Wang, Y.X., Lee, C.H., Tiep, S., Yu, R.T., Ham, J., Kang, H., Evans, R.M. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell, 2003, 113, 159-170.
30. Spiegelman, B.M. PPARgamma: adipogenesis regulator and thiazolidinedione receptor. Diabetes, 1998, 47, 507-514.
31. Marx, N., Duez, H., Fruchart, J.-C., Staels, B. Peroxisome proliferator-activated receptors and atherogenesis. Circ. Res., 2004, 94, 1168-1178.
32. Chinetti, G., Lestavel, S., Bocher, V., Remaley, A.T., Neve, B., Torra, I.P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H.B., Fruchart, J.C., Clavey, V., Staels, B. PPARalpha and PPARgamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med., 2001, 7, 53-58.
33. Forman, B.M., Chen, J., Evans, R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. USA, 1997, 94, 4312-4317.
34. Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., Fruchart, J.C. Mechanism of action of fibrates on lipid and liporotein metabolism. Circulation, 1998, 98, 2088-2093.
35. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Wilson, T.M., Kliewer, S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARg). J. Biol. Chem., 1995, 270, 12953-12956.
36. Qi, C., Zhu, Y., Reddy, J.K. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell. Biochem. Biophys., 2000, 32, 187-204.
37. Llopis, J., Westin, S., Ricote, M., Wang, Z., Cho, C.Y., Kurokawa, R., Mullen, T.M., Rose, D.W., Rosenfeld, M.G., Tsien, R.Y., Glass, C.K. Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription. Proc. Natl. Acad. Sci. USA, 2000, 97, 4363-4368.
38. Rosenfend, M.G., Glass, C.K. Coregulator codes of transcriptional regulation by nuclear receptors. J. Biol. Chem., 2001, 276, 36865-36868.
39. Torra, I.P., Chinetti, G., Duval, C., Fruchart, C., Staels, B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr. Opin. Lipidol., 2001, 12, 245-254.
40. Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozalo, K., Wahli, W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA, 1993, 90, 2160-2164.
41. Delerive, P., De Bosscher, K., Venden Berghe, W., Fruchart, J.-C., Haegeman, G., Staels, B. DNA binding-independent induction of IkBa gene transcription by PPARalpha. Mol. Endocrinol., 2002, 16, 1029-1039.
42. Li, A.C., Glass, C.K. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res., 2004, 45, 2161-2173.
43. Blanquart, C., Mansouri, R., Paumelle, R., Fruchart, J.C., Staels, B., Glineur, C. The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. Mol. Endocrinol., 2004, 18, 1906-1918.
44. Lee, C.H., Urbiztondo, N., Liao, D., Boiswert, W.A., Evans, R.M. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science, 2003, 302, 453-457.
45. Xu, H.E., Stanley, T.B., Montana, V.J., Lambert, M.H., Shearer, B.G., Cobb, J.E., McKee, D.D., Galardi, C.M., Plunket, K.D., Nolte, R.T., Parks, D.J., Moore, J.T., Kliewer, S.A., Wilson, T.M., Stimmel, J.B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature, 2002, 415, 813-817.
46. Shalev, A., Siegrist-Kaiser, C.A., Yen, P.M., Wahli, W., Burger, A.G., Chin, W.W., Meier, C.A. The peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin. Endocrinology, 1996, 137, 4499-4502.
47. Barger, P.M., Browning, A.C., Garner, A.N., Kelly, D.P. p38 mitogen-activated protein kinase activates peroxisome proliterator-activated receptor alpha: a potential role in the cardiac metabolic stress response. J. Biol. Chem., 2001, 276, 44495-44501.
48. Juge-Aubry, C.E., Hammar, E., Siegrist-Kaiser, C., Pernin, A., Takeshita, A., Chin, W.W., Burger, A.G., Meier, C.A. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain. J. Biol. Chem., 1999, 274, 10505-10510.
49. Lusis, A.J. Atherosclerosis. Nature, 2000, 407, 233-241.
50. Binder, C.J., Chang, M.K., Shaw, P.X., Miller, Y.I., Hatvigsen, K., Dewan, A., Witztum, J.L. Innate and acquired immunity in atherogenesis. Nat. Med., 2002, 8, 1218-1226.
51. Libby, P. Inflammation in atherosclerosis. Nature, 2002, 420, 868-874.
52. Ross, R. Atherosclerosis - An inflammatory disease. N. Engl. J. Med., 1999, 340, 115-126.
53. Inoue, I., Shino, K., Noji, S., Awata, T., Katayama, S. Expression of peroxisome proliferator-activated receptor alpha (PPARa) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun., 1998, 246, 370-374.
54. Marx, N., Sukhova, G.K., Collins, T., Libby, P., Plutzky, J. PPARalpa activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 1999, 99, 3125-3131.
55. Neve, B.P., Corseaux, D., Chinetti, G., Zawadzki, C., Fruchart, J.-C.D.P., Staels, B., Jude, B. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation, 2001, 103, 207-212.
56. Marx, N., Kehrle, B., Kohlhammer, K., Grub, M., Koenig, W., Hombach, V., Libby, P., Plutzky, J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res., 2002, 90, 1135-1143.
57. Kim, H., Haluzik, M., Asghar, Z., Yau, D., Joseph, J.W., Fernandez, A.M., Reitman, M.L., Yakar, S., Stannard, B., Heron-Milhavet, L., Wheeler, M.B., LeRoith, D. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes, 2003, 52, 1770-1778.
58. Ye, J.M., Doyle, P.M., Iglesias, M.A., Watson, D.G., Cooney, G.J., Kraegen, E.W. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high-fed rats: comparison with PPAR-gamma activation. Diabetes, 2005, 50, 411-417.
59. Chou, C.J., Haluzik, M., Gregory, C., Dietz, K.R., Vinson, C., Gavrilova, O., Reitman, M.L. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and revesres insulin resistance in lipoatrophic A-ZIP/F-1 mice. J. Biol. Chem., 2002, 277, 24484-24489.
60. Saitoh, K., Mori, T., Kasai, H., Nagayama, T., Tsuchiya, A., Ohbayashi, S. Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I: anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits. Nippon Yakurigaku Zasshi, 1995, 106, 41-50.
61. Saitoh, K., Mori, T., Kasai, H., Nagayama, T., Ohbayashi, S. Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. II: antiatheromatous effects are independent of its hypolipidemic effect in hereditary hyperlipidemic rabbits. Nippon Yakurigaku Zasshi, 1995, 106, 51-60.
62. Ericsson, C.G., Hamsten, J., Nilsson, L., Grip, L., Svane, B., de Faire, U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet, 1996, 347, 849-853.
63. Nawa, T., Nawa, M.T., Cai, Y., Zhang, C., Uchimura, I.N.S., Numano, F., Kitajima, S. Repression of TNF-alpha-induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3. Biochem. Biophys. Res. Commun., 2000, 275, 406-411.
64. Rival, Y., Beneteau, N., Taillandier, T., Pezet, M., Dupont-Passelaigue, E., Patoiseau, J.F., Junquero, D., Colpaert, F.C., Delhon, A. PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol., 2002, 435, 143-151.
65. Dashwood, M.R., Tsui, J.C. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis, 2002, 160, 297-304.
66. Delerive, P., Martin-Nizard, F., Chinetti, G., Trottein, F., Fruchart, J.-C., Najib, J., DuriezP., Staels, B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res., 1999, 85, 394-402.
67. Martin-Nizard, F., Furman, C., Delerive, P., Kandoussi, A., Fruchart, J.C., Staels, B., Duriez, P. Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J. Cardiovasc. Pharmacol., 2002, 40, 822-831.
68. Goya, K., Sumitani, S., Xu, X., Kitamura, T., Yamamoto, H., Kurebayashi, S., Saito, H., Kouhara, H., Kasayama, S., Kawase, I. Peroxisome proliferator-activated receptor gamma agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2003, 24, 658-663.
69. Omura, K., Kobayashi, S., Mizukami, Y., Mogami, K., Todoroki-Ikeda, N., Miyake, T., Matsuzaki, M. Eicosapentanoic acid (EPA) induces Ca(2+)-independent activation and translocation of endothelial nitric oxide synthase and endothelium-dependent vasorelaxation. FEBS Lett., 2001, 487, 361-366.
70. Harrison, D., Griendling, K.K., Landmesser, U., Hornig, B., Drexler, H. Role of oxidative stress in atherosclerosis. Am. J. Cardiol., 2003, 91, 7A-11A.
71. Ogita, H., Liao, J. Endothelial function and oxidative stress. Endothelium, 2004, 11, 123-132.
72. Plutzky, J. Peroxisome proliferator-activated receptors in endothelial biology. Curr. Opin. Lipidol., 2001, 12, 511-518.
73. Pasceri, V., Cheng, J.S., Willerson, J.T., Yeh, E.T., Chang, J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1induction in human endothelial cells by anti-atherosclerotic drugs. Circulation, 2001, 103, 2531-2534.
74. Lee, H., Shi, W., Tontonoz, P., Wang, S., Subbanagounder, G., Hedrick, C.C., Hama, S., Borromeo, C., Evans, R.M., Berliner, J.A., Nagy, L. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ. Res., 2000, 87, 516-521.
75. Bursil, C.A., Channon, K.M., Greaves, D.R. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr. Opin. Lipidol., 2004, 15, 145-149.
76. Gu, L., Okada, Y., Clinton, S.K., Gerard, C., Sukhova, G.K., Libby, P., Rollins, B.J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell, 1998, 2, 275-281.
77. Kaplan, M., Aviram, M. Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin. Chem. Lab. Med., 1999, 37, 777-787.
78. Jang, C., Ting, A.T., Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 2004, 391, 82-86.
79. Marx, N., Mackman, N., Schönbeck, U., Yilmaz, N., Hombach, V., Libby, P., Plutzky, J. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation, 2001, 103, 213-219.
80. Moons, A.H., Levi, M., Peters, R.J. Tissue factor and coronary artery disease. Cardiovasc. Res., 2002, 53, 313-325.
81. Libby, P. Current concepts of the pathogenesis of the acute coronary syndrome. Circulation, 2001, 104, 365-372.
82. Duez, H., Fruchart, J., Staels, B. PPARs in inflammation, atherosclerosis and thrombosis. J. Cardiovasc. Risk, 2001, 8, 184-194.
83. Shu, H., Wong, B., Zhou, G., Li, Y., Berger, J., Woods, J.W., Wright, S.D., Cai, T.Q. Activation of PPARalpha and gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem. Biophys. Res. Commun., 2000, 267, 365-372.
84. Rival, Y., Beneteau, N., Chapuis, V., Taillandier, T., Lestienne, F., Dupont-Passelaigue, E., Patoiseau, J.F., Colpaert, F.C., Junquero, D. Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages. DNA Cell. Biol., 2004, 23, 283-292.
85. Kolodgie, F.D., Narula, J., Burke, A.P., Haider, N., Farb, A., Hui-Liang, Y., Smialek, J., Virmani, R. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am. J. Pathol., 2000, 157, 1259-1268.
86. Kockx, M.M., Herman, A.G. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc. Res., 2000, 45, 736-746.
87. Chinetti, G., Lestavel, S., Fruchart, J.C., Clavey, V., Staels, B. Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ. Res., 2003, 92, 212-217.
88. Chinetti, G., Lestavel, S., Bocher, V., Remaley, A.T., Neve, B., Torra, I.P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H.B., Fruchart, J.C., Clavey, V., Staels, B. PPARalpha and gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med., 2001, 7, 53-58.
89. Bouly, M., Masson, D., Gross, B., Jang, X.C., Fievet, C., Castro, G., Tall, A.R., Fruchart, J.C., Staels, B., Lagrost, L., Luc, G. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargements in mice treated with fenofibrate. J. Biol. Chem., 2001, 276, 25841-25847.
90. Chinetti, G., Gbaguidi, F.G., Griglio, S., Mallat, Z., Antonucci, M., Poulain, P., Chapman, J., Fruchart, J.C., Tedgui, A., Najib-Fruchart, J., Staels, B. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation, 2000, 101, 2411-2417.
91. Haraguchi, G., Kobayashi, Y., Brown, M.L., Tanaka, A., Isobe, M., Gianturco, S.H., Bradley, W.A. PPARalpha and PPARgamma activators suppress the monocyte-macrophage apoB-48 receptor. J. Lipid Res., 2003, 44, 1224-1231.
92. Gbaguidi, F.G., Chinetti, G., Milosavljevic, D., Teissier, E., Chapman, J., Olivecrona, G., Fruchart, J.C., Griglio, S., Fruchart-Najib, J., Staels, B. Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages. FEBS Lett., 2002, 512, 85-90.
93. Li, L., Beauchamp, M.C., Renier, G. Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis, 2002, 165, 101-110.
94. Diep, Q.N., Intengan, H.D., Schiffrin, E.L. Endothelin-1 attenuates omega-3 fatty acid-induced apoptosis by inhibition of caspase 3. Hypertension, 2000, 35, 287-291.
95. Diep, Q.N., Touyz, R.M., Schiffrin, E.L. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha activator, induces apoptosis in vascular smooth muscle cells by activation of p38 mitogen-activated protein kinase. Hypertension, 2000, 36, 851-855.
96. Flynn, D., Byrne, C.D., Baglin, T.P., Weissberg, P.L., Bennett, M.R. Thrombin generation by apoptotic vascular smooth muscle cells. Blood, 1997, 89, 4378-4384.
97. Bennett, M.R. Apoptosis in vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc. Res., 1999, 41, 361-368.
98. Bauriedel, G., Hutter, R., Welsch, U., Bach, R., Sievert, H., Luderitz, B. Role of smooth muscle cell death in advanced coronary primary lesions: implications for plaque instability. Cardiovasc. Res., 1999, 41, 480-488.
99. Dhume, A.S., Agrawal, D.K. Inability of vascular smooth muscle cells to proceed beyond S phase of cell cycle and increased apoptosis in symptomatic carotid artery disease. J. Vasc. Surg., 2003, 38, 155-161.
100. Dhume, A.S., Soundararajan, K., Hunter, W.J., Agrawal, D.K. Comparison of vascular smooth muscle cell apoptosis and fibrous cap morphology in symptomatic and asymptomatic coronary artery disease. Ann. Vasc. Surg., 2003, 17, 1-8.
101. Stary, H.C., Chandler, A.B., Dinsmore, R.E., Fuster, V., Glagov, S., Insull, W.Jr., Rosenfeld, M.E., Schwartz, C.J., Wagner, W.D., Wissler, R.W. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 1995, 92, 1355-1374.
102. Kockx, M.M., DeMeyer, G.R., Muhring, J., Jacob, W., Bult, H., Herman, A.G. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation, 1998, 97, 2307-2315.
103. Stoneman, V.E.A., Bennett, M.R. Role of apoptosis in atherosclerosis and its therapeutic implications. Clin. Sci., 2004, 107, 343-354.
104. Ludewig, B., Laman, J.D. The in and out of monocytes in atherosclerotic plaques: balancing inflammation through migration. Proc. Natl. Acad. Sci. USA, 2004, 101, 11529-11530.
105. Millonig, G., Schwentner, C., Mueller, P., Mayerl, C., Wick, G. The vascular-associated lymphoid tissue: a new site of local immunity. Curr. Opin. Lipidol., 2001, 12, 547-553.
106. Madej, A., Okopien, B., Kowalski, J., Zielinski, M., Wysocki, J., Szygula, B., Kalina, Z., Herman, Z.S. Effects of fenofibrate on plasma cytokine concentration in patients with atherosclerosis and hyperlipoproteinemia IIb. Int. J. Clin. Pharmacol. Ther., 1998, 36, 345-349.
107. Okopien, B., Cwalina, L., Lebek, M., Kowalski, J., Zielinski, M., Wisniewska-Wanat, M., Kalina, Z., Herman, Z.S. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. Int. J. Clin. Pharmacol. Ther., 2001, 39, 551-557.
108. Durrington, P.N., Mackness, M.I., Bhatnagar, D., Julier, K., Prais, H., Arrol, S., Morgan, J., Wood, G.N. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinemia. Atherosclerosis, 1998, 138, 217-225.
109. Lassila, R., Peltonen, S., Lepantalo, M., Saarinen, O., Kauhanen, P., Manninen, V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler. Thromb., 1993, 13, 1738-1742.
110. Gervois, P., Kleemann, R., Pilon, A., Percevault, F., Koenig, W., Staels, B., Kooistra, T. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor alpha activator fenofibrate. J. Biol. Chem., 2004, 279, 16154-16160.
111. D'Costa, M.A., Angel, A. Inhibition of hormone-stimulated lipolysis by clofibrate: a possible mechanism for its hypolipidemic action. J. Clin. Invest., 1975, 55, 138-148.
112. Heller, F., Harvengt, C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipidaemic subjects. Eur. J. Clin. Pharmacol., 1983, 25, 57-63.
113. Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A.M., Heyman, R.A., Briggs, M., Deeb, S., Staels, B., Auwerx, J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J., 1996, 15, 5336-5348.
114. Staels, B., Vu-Dac, N., Kosykh, V.A., Saladin, R., Fruchart, J.C., Dallongeville, J., Auwerx, J. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J. Clin. Invest., 1995, 65, 705-712.
115. Yoshida, H., Ishikawa, T., Ayaori, M., Shige, H., Ito, T., Suzukawa, M., Nakamura, H. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study. Atherosclerosis, 1998, 139, 179-187.
116. Lemieux, I., Laperriere, L., Dzavik, V., Tremblay, G., Bourgeois, J., Despres, J.P. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis, 2002, 162, 363-371.
117. Vu-Dac, N., Chopin-Delannoy, S., Gervois, P., Bonnelye, E., Martin, G., Fruchart, J.C., Laudet, V., Staels, B. The nuclear receptors peroxisome proliferator-activated receptor alpha and Reverbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J. Biol. Chem., 1998, 273, 25713-25720.
118. Vu-Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J., Fruchart, J.C., Staels, B., Auwerx, J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J. Clin. Invest., 1995, 96, 741-750.
119. Verges, B. Clinical interest of PPARs ligands. Diabetes Metab., 2004, 30, 7-12.
120. Krause, B.R., Princen, H.M. Lack of predictability of classical animal models to hypolipidemic activity: a good time for mice? Atherosclerosis, 1998, 140, 15-24.
121. Diep, Q.N., Amiri, F., Touyz, R.M., Cohn, J.S., Endemann, D., Schiffrin, E.L. PPARalpha activator effects on Ang II-induced vasular oxidative stress and inflammation. Hypertension, 2002, 40, 866-871.
122. Iglarz, M., Touyz, R.M., Amiri, F., Lavoie, M.F., Diep, Q.N., Schiffrin, E.L. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 45-51.
123. Fu, T., Mukhopadhyay, D., Davidson, N.O., Borensztajn, J. The peroxisome-proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice. J. Biol. Chem., 2004, 279, 28662-28669.
124. Fu, T., Kashireddy, P., Borensztjn, J. The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem. J., 2003, 373, 941-947.
125. Duez, H., Chao, Y.S., Hernandez, M., Torpier, G., Poulain, P., Mundi, S., Mallat, Z., Teissier, E., Burton, C.A., Tedgui, A., Fruchart, J.C., Fievet, C., Wright, S.D., Staels, B. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J. Biol. Chem., 2002, 277, 48051-48057.
126. Tordjman, K., Bernal-Mizrachi, C., Zemany, L., Weng, S., Feng, C., Zhang, F., Leone, T.C., Coleman, T., Kelly, D.P., Semenkovich, C.F. Peroxisome proliferator-activated receptor alpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest., 2001, 107, 1025-1034.
127. Li, A.C., Binder, C.J., Gutierez, A., Brown, K.K., Plotkin, C.R., Pattison, J.W., Valledor, A.F., Davis, R.A., Wilson, T., Witztum, J.L., Palinski, W., Glass, C.K. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta and gamma. J. Clin. Invest., 2004, 114, 1564-1576.
128. Verreth, W., De Keyzer, D., Pelat, M., Verhamme, P., Ganame, J., Bielicki, J.K., Mertens, A., Quarck, R., Benhabiles, N., Marguerie, G., Mackness, B., Mackness, M., Ninio, E., Herregods, M.C., Balligand, J.L., Holvoet,P. Weight loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation, 2004, 110, 3529-3269.
129. Liang, C.P., Han, S., Okamoto, H., Carnemolla, R., Tabas, I., Accili, D., Tall, A.R. Increased CD36 protein as a response to defective insulin signaling in macrophages. J. Clin. Invest., 2004, 113, 764-773.
130. Capell, W.H., DeSouza, C.A., Poirier, B., Bell, M.L., Stauffer, B.L., Weil, K.M., Hernandez, T.L., Eckel, R.H. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 307-313.
131. Seiler, C., Suter, T.M., Hess, O.M. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J. Am. Coll. Cardiol., 1995, 26, 1615-1622.
132. Avogaro, A., Miola, M., Favaro, A., Gottardo, L., Pacini, G., Manzato, E., Zambon, S., Sacerdoti, D., de Kreutzenberg, S., Piliego, T., DelPrato, S. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilation in type 2 diabetic patients. Eur. J. Clin. Invest., 2001, 31, 603-609.
133. Evans, M., Anderson, R.A., Graham, J., Ellis, G.R., Morris, K., Davies, S., Jackson, S.K., Lewis, M.J., Frenneaux, M.P., Rees, A. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation, 2000, 101, 1773-1779.
134. Playford, D.A., Watts, G.F., Best, J.D., Burke, V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am. J. Cardiol., 2002, 90, 1254-1257.
135. Meade, T., Zuhrie, R., Cook, C., Cooper, J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. Br. Med. J., 2002, 325, 1139-1143.
136. Elkeles, R.S., Diamond, J.R., Poulter, C., Dhanjil, S., Nicolaides, A.N., Mahmood, S., Richmond, W., Mather, H., Sharp, P., Feher, M.D. Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate: the St. Mary's Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) study. Diabetes Care, 1998, 21, 641-648.
137. Frick, M.H., Elo, O., Haapa, K., Heinonen, O.P., Heinsalmi, P., Helo, P., Huttunen, J.K., Kaitaniemi, P., Koskinen, P., Manninen, V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in
138. Tenkanen, L., Mänttäri, M., Manninen, V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Circulation, 1995, 92, 1779-1785.
139. Frick, M.H., Manninen, V., Huttunen, J.K., Tenkanen, L., Manttari, M. HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study. Drugs, 1990, 40, 7-12.
140. Manninen, V., Hurrunen, J.K., Heinonen, O.P., Frick, M.H. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am. J. Cardiol., 1989, 63, 42-47.
141. Koskinen, P., Manttari, M., Manninen, V., Huttunen, J.K., Heinonen, O.P., Frick, M.H. Coronary heart disease in NIDDM patients in the Helsinki Heart Study. Diabetes Care, 1992, 15, 820-825.
142. Rubins, H.B., Robins, S.J., Collins, D., Fye, C.L., Anderson, J.W., Elam, M.B., Faas, F.H., Linares, E., Schaefer, E.J., Schectman, G., Wilt, T.J., Wittes, J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density liporotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med., 1999, 341, 410-418.
143. Rubins, H.B., Robins, S.J., Collins, D., Nelson, D.B., Elam, M.B., Schaefer, E.J., Faas, F.H., Anderson, J.W. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs High-density lipoprotein Intervention Trial (VA-HIT). Arch. Intern. Med., 2002, 162, 2597-2604.
144. Robins, S.J., Bloomfield-Rubins, H., Faas, F.H., Schaeffer, E.J., Elam, M.B., Anderson, J.W., Collins, J.W. Insulin resistance and cardiovascular events with low HDL cholesterol. Diabetes Care, 2003, 26, 1513-1517.
145. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation, 2000, 102, 21-27.
146. Haffner, S.M. Secondary prevention of coronary heart disease. Circulation, 2000, 102, 2-4.
147. Ruotolo, G., Ericsson, C.-G., Tettamanti, C., Karpe, F., Grip, L., Svane, B., Nilsson, J., de Faire, U., Hamsten, A. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J. Am. Coll. Cardiol., 1998, 32, 1648-1656.
148. Frick, M.H., Syvanne, M., Nilsson, J., Nieminen, M.S., Kauma, H., Majahalme, S., Virtanen, V., Kesaniemi, Y.A., Pasternack, A., Taskinen, M.R. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation, 1997, 96, 2137-2143.
149. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet, 2001, 357, 905-910.
150. Ohsawa, H., Uchida, Y., Fujimori, Y., Hirose, J., Noike, H., Tokuhiro, K., Kawamura, K., Kanai, M., Sakuragawa, H., Hitsumoto, A., Aoyagi, K., Sakurai, T., Sato, S., Yoshinaga, K., Kaku, M., Ozegawa, M., Morio, H., Yamada, K., Terasawa, K., Uchida, Y., Ohshima, T. Angioscopic evaluation of stabilizing effects of an antilipemic agent, bezafibrate, on coronary artery disease: a multicenter prospective study. Jpn. Heart J., 2002, 43, 319-331.
151. Flavell, D.M., Pineda Torra Y., Jamshidi, Y., Evans, D., Diamond, J.R., Elkeles, R.S., Bujac, S.R., Miller, G., Talmud, P.J., Staels, B., Humphries, S.E. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia, 2000, 43, 673-680.
152. Flavell, D.M., Jamshidi, Y., Hawe, E., Pineda Torra, I., Taskinen, M.-R., Frick, M.H., Nieminen, M.S., Kesäniemi, A., Pasternack, A., Staels, B., Miller, G., Humphries, S.E., Talmud, P.J., Syvanne, M. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation, 2002, 105, 1440-1445.
153. Lacquemant, C., Leprete, F., Pineda Torra, I., Manraj, M., Charpentier, G., Ruiz, J., Staels, B., Froguel, P. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab., 2000, 26, 393-401.
154. Brousseau, M.E., Tai, E.S., Collins, D., O'Connor, J.J., Cordovas, J.M., Rubins, H.B., Robins, S.J., Schaefer, E.J. A common variant in the peroxisome proliferator-activated receptor alpha gene is associated with decreased risk for new coronary events in diabetic and insulin resistant subjects in VA-HIT. Data presented at the American Heart Association meeting, Orlando, Florida, November, 2003.
155. Gouni-Berthold, I., Giannakidou, E., Müller-Wieland, D., Faust, M., Kotzka, J., Berthold, H.K., Krone, W. Association between the PPARalpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. Am. Heart J., 2004, 147, 1117-1124.
156. Sapone, A., Peters, J.M., Sakai, S., Tomita, S., Papiha, S.S., Dai, R., Friedman, F.K., Gonzalez, F.J. The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterisation of two natural allelic variants. Pharmacogenetics, 2000, 10, 321-333.
157. Uppenberg, J., Svensson, C., Jaki, M., Bertilsson, G., Jendeberg, L., Berkenstam, A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J. Biol. Chem., 1998, 273, 31108-31112.
158. Brzozowski, A.M., Pike, A.C., Dauter, Z., Hubbard, R.E., Bonn, T., Engstrom, O., Ohman, L., Greene, G.L., Gustafsson, J.A., Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 1997, 389, 753-758.
159. Gorla-Bajszczak, A., Juge-Aubry, C., Pernin, A., Burger, A.G., Meier, C.A. Conserved amino acids in the ligand-binding and tau(i) domains of the peroxisome proliferator-activated receptor alpha are necessary for heterodimerization with RXR. Mol. Cell. Endocrinol., 1999, 147, 37-47.
160. Wilson, T.M., Brown, P.J., Sternbach, D.D., Henke, B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem., 2000, 43, 527-550.
161. Miyachi, H. Recent progress of the research on peroxisome proliferator-activated receptor alpha-selective ligands. Drugs, 2004, 7(746), 754.
162. Skrumsager, B.K., Nielsen, K.K., Müller, M., Pabst, G., Drake, P.G., Edsberg, B. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARalpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J. Clin. Pharmacol., 2005, 43, 1244-1256.
163. Ericsson, H., Hamren, B., Bergstrand, S., Elebring, M., Fryklund, L., Heijer, M., Öhman, K.P. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. Drug Metab. Dispos., 2004, 32, 923-929.
164. Hegarty, B.D., Furler, S.M., Oakes, N.D., Kraegen, E.W., Cooney, G.J. Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo-a study using the novel PPARalpha/gamma agonist tesaglitazar. J. Clin. Endocrinol. Metab., 2004, 145, 3158-3164.
165. Pickavance, L.C., Brand, C.L., Wassermann, K., Wilding, J.P.H. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br. J. Pharmacol., 2005, 144, 308-316.
166. Chakrabarti, R., Vikramadithyan, R.K., Misra, P., Hiriyan, J., Aichur, S., Amarla, R.K., Ershome, C., Uresh, J., Agalopalan, R. Ragaglitazar:a novel PPARalpha & PPARgamma agonist with potent lipid-lowering and insulin sensitzing efficacy in animal models. Br. J. Pharmacol., 2003, 140, 527-537.
167. Saad, M.F., Greco, S., Osei, K., Lewin, A.J., Edwards, C., Nunez, M., Reinhardt, R.R. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects. Diabetes Care, 2004, 27, 1324-1329.
168. Lebovitz, H.E., Banerji, M. Insulin resistance and its treatment by thiazolidinediones. Recent Prog. Horm. Res., 2001, 56, 265-294.
169. Normen, L., Frohlich, J., Montaner, J., Harris, M., Elliott, T., Bondy, G. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care, 2004, 27, 2241-2242.
170. The FIELD Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Loweing in diabetes (FIELD) study. Cardiovasc. Diabetol., 2004, 3, 1-11.